Peptides

Empower Pharmacy to Compound Six Peptides Under HHS Interim Policy

Providers and patients gain a regulated, accountable path to peptide medications through Empower’s 503A pharmacy 

Empower Pharmacy, the nation’s premier 503A compounding pharmacy and 503B outsourcing facility, announced that its 503A pharmacy is preparing to compound select peptide medications under the U.S. Department of Health and Human Services’ (HHS) interim enforcement discretion policy.  

Empower is working to make all six peptides covered by the guidance – BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax – available as single ingredient formulations in December, subject to applicable requirements and a valid prescription for an individual patient. In addition, providers may prescribe combinations of these individual peptides when clinically appropriate, offering greater flexibility to tailor care to each patient.

 

“Demand for peptides hasn’t gone away, but too often, patients have turned to sources without meaningful oversight,” said Shaun Noorian, Founder and Chief Executive Officer of Empower Pharmacy. “HHS’ interim policy creates a more accountable pathway for peptides through patient-specific prescriptions, licensed pharmacies, verified ingredients, and reporting to FDA. That’s progress for provider and patient access alike.” 

 

At Empower, peptide preparations compounded under the HHS pathway will follow the same quality processes used across all its medications, including sourcing from FDA-registered manufacturers, testing materials, and validated production.

“Behind every prescription is a person, and often a family, trusting us to get the details right,” said Jonathan Abrarpour, President of Empower Pharmacy. “That’s why we’re taking a deliberate approach to sourcing, testing, and operational readiness before bringing these preparations to market. Expanding access matters, but so does the responsibility that comes with it.” 

For over 17 years, Empower has made personalized medicine accessible, giving providers the flexibility to match treatment to the individual patient rather than the other way around. Peptides are the newest chapter in that work, but the company’s commitment to expanding access to quality, affordable medications remains unchanged.   

New Peptide Preparations Are On The Way

Get Peptide Updates

 

Disclaimer: Compounded drug products are available only pursuant to a valid prescription from your licensed healthcare provider. Compounded drug products are not FDA-approved and have not been evaluated by the FDA for safety or efficacy.   

Related Stories

Peptide Therapy: Where Do We Go From Here? 5 Takeaways From Our Recent Webinar
people sitting around a table reviewing medical documentation What the FDA Pharmacy Compounding Advisory Committee’s July 2026 Peptide Meeting Means for Patients and Providers
Vials of medicine in a tray being held by two gloved hands What Are Compounding Pharmacies? Your Top Questions Answered